Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies

Panelists discuss how optimal biomarker testing requires careful balancing of multiple factors. Critical considerations include the turnaround time needed to inform timely treatment decisions, the comprehensiveness of testing panels to identify actionable mutations, and the demonstrated clinical utility of results for guiding therapy selection. Patient-specific factors such as cancer type, stage, prior treatments, and urgency of therapeutic decisions must guide test selection.

Panelists discuss how comprehensive biomarker testing enables detection of actionable mutations across cancer types, informing targeted therapy selection. This broad molecular profiling approach can reveal treatment opportunities regardless of tumor origin.

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.